Portal de Periódicos da CAPES

Chronic treatment with N -acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking

2019; Wiley; Volume: 7; Issue: 1 Linguagem: Inglês

10.14814/phy2.13958

2051-817X

Gregory L. Powell, Jonna M. Leyrer‐Jackson, Julianna Goenaga, Mark D. Namba, José Antonio López Pina, Sade Spencer, Neringa Stankeviciute, Danielle Schwartz, Nicholas P. Allen, Armani P. Del Franco, Erin A. McClure, M. Foster Olive, Cassandra D. Gipson,

Nicotinic Acetylcholine Receptors Study

N-acetylcysteine (NAC), a promising glutamatergic therapeutic agent, has shown some clinical efficacy in reducing nicotine use in humans and has been shown to reverse drug-induced changes in glutamatergic neurophysiology. In rats, nicotine-seeking behavior is associated with alterations in glutamatergic plasticity within the nucleus accumbens core (NAcore). Specifically, cue-induced nicotine-seeking is associated with rapid, transient synaptic plasticity (t-SP) in glutamatergic synapses on NAcore medium spiny neurons. The goal of the present study was to determine if NAC reduces nicotine-seeking behavior and reverses reinstatement-associated NAcore glutamatergic alterations. Rats were extinguished from nicotine self-administration, followed by subchronic NAC administration (0 or 100 mg/kg/d) for 4 days prior to cue-induced reinstatement. NAcore synaptic potentiation was measured via dendritic spine morphology and mRNA and protein of relevant glutamatergic genes were quantified. Nicotine-seeking behavior was not reduced by subchronic NAC treatment. Also, NAcore transcript and protein expression of multiple glutamatergic genes, as well as spine morphological measures, were unaffected by subchronic NAC. Finally, chronic NAC treatment (15 days total) during extinction and prior to reinstatement significantly decreased extinction responding and reduced reinstatement of nicotine-seeking compared to vehicle. Together, these results suggest that chronic NAC treatment is necessary for its therapeutic efficacy as a treatment strategy for nicotine addiction and relapse.